GlobalData on MSN3d
Roche wins first-line approval for PI3K inhibitor combo in breast cancer
The US FDA approved Itovebi in combination with Pfizer’s Ibrance and AstraZeneca’s Faslodex for certain breast cancer ...
BioSpace4d
Roche Wins First-Line Breast Cancer Nod for Oral PI3K Blocker, Projects $2.3B in Peak Sales
With the regulatory approval for advanced breast cancer, Roche’s inavolisib is a potential challenger to Novartis’ PI3K ...
Medpage Today on MSN4d
PI3K Inhibitor Wins FDA Approval for Advanced Breast Cancer
The FDA approved the PI3K-pathway inhibitor inavolisib (Itovebi) for use in combination with palbociclib (Ibrance) and ...
FiercePharma4d
Roche burnishes breast cancer portfolio with FDA approval for Itovebi, a threat to Novartis and AZ
As Roche comes under competitive pressure on its breast cancer business, the Swiss company hopes a new drug will add a ...
BioSpace1d
5 Accelerated Approvals Gone Wrong
Since its inception in 1992, the FDA’s accelerated approval pathway has helped shepherd nearly 300 new drugs to the market.
Buy Rating for Relay Therapeutics: Promising Pipeline and Positive PI3Ka Inhibitor Prospects
H.C. Wainwright analyst Robert Burns reiterated a Buy rating on Relay Therapeutics (RLAY – Research Report) today and set a price target ...
pharmaphorum4d
Roche gets FDA green light for breast cancer drug Itovebi
Novartis' Piqray/Vijoice (alpelisib) is the only PIK3CA inhibitor to have reached the market for breast cancer, having been ...
WebMD20h
New Drug Approved for Common Type of Breast Cancer Recurrence
A new breast cancer drug has received quick federal approval after a clinical trial showed it could more than double the time before a common type of breast cancer recurrence worsens.
News Medical on MSN15h
Semaglutide enhances cognitive abilities and reduces Alzheimer’s pathology in mice and human brain models
Researchers find that Semaglutide improves cognitive function and reduces amyloid and tau pathology in Alzheimer's disease ...